Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2026
[Correction of autonomic nervous system disorders: results from an observational study].
СтатьяНаблюдательное исследованиеАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Skipetrova L A, Cheremin R A, Savinkova I G
Аннотация
OBJECTIVE: To evaluate the efficacy and safety of Prospekta in real-world clinical settings for the treatment of autonomic nervous system (ANS) disorders in patients presenting with asthenia.
MATERIAL AND METHODS: This observational study included 425 patients, comprising individuals of both sexes aged 18 to 55 years (mean age 38.4±10.8 years), who reported symptoms associated with ANS disorders and fatigue. Participants received Prospekta, administered as 1 tablet twice daily for 4 weeks. The severity of ANS disorders was evaluated using the 4DSQ (Four Dimensional Symptom Questionnaire) somatoform disorder scale. Quality of life was measured employing the EQ-5D-3L questionnaire. The mean Clinical Global Impression - Improvement (CGI-I) score, along with the nature and frequency of adverse events during treatment, their severity, relationship to Prospekta, and outcomes, were comprehensively recorded.
RESULTS: Patients were categorized into three groups based on their initial level of somatization. A statistically significant reduction in the mean 4DSQ score was noted across all groups, with the most significant improvement observed in Group 3 (characterized by a severely elevated level of somatization) (p<0.001). Additionally, an improvement in quality of life, as assessed by the EQ-5D-3L questionnaire, was statistically significant. A positive correlation was identified between the decrease in somatization severity and reductions in both blood pressure and heart rate.
CONCLUSION: The use of Prospekta in patients with ANS disorders and asthenia results in a significant decrease in somatization, which corresponds with normalization of cardiovascular function and improvements in quality of life.
MATERIAL AND METHODS: This observational study included 425 patients, comprising individuals of both sexes aged 18 to 55 years (mean age 38.4±10.8 years), who reported symptoms associated with ANS disorders and fatigue. Participants received Prospekta, administered as 1 tablet twice daily for 4 weeks. The severity of ANS disorders was evaluated using the 4DSQ (Four Dimensional Symptom Questionnaire) somatoform disorder scale. Quality of life was measured employing the EQ-5D-3L questionnaire. The mean Clinical Global Impression - Improvement (CGI-I) score, along with the nature and frequency of adverse events during treatment, their severity, relationship to Prospekta, and outcomes, were comprehensively recorded.
RESULTS: Patients were categorized into three groups based on their initial level of somatization. A statistically significant reduction in the mean 4DSQ score was noted across all groups, with the most significant improvement observed in Group 3 (characterized by a severely elevated level of somatization) (p<0.001). Additionally, an improvement in quality of life, as assessed by the EQ-5D-3L questionnaire, was statistically significant. A positive correlation was identified between the decrease in somatization severity and reductions in both blood pressure and heart rate.
CONCLUSION: The use of Prospekta in patients with ANS disorders and asthenia results in a significant decrease in somatization, which corresponds with normalization of cardiovascular function and improvements in quality of life.